>>Think of the decision as if your job depended on it - if you licensed it after NVS passed and it eventually failed in phase 2 trials. Everyone would have pointed to the NVS as a red flag that the drug didnt work and you'd be out on the street.
If it's my job, the fact the NVS pass will be one of the inputs I will consider - but won't be an important one.
NVS owns ~50% of IDIX already, they will participate the potential of the drug either directly or indirectly anyways.
Maybe NVS is buying the whole thing - why partner...;)
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.